Immunogenicity of COVID-19 Vaccine Co-administration With Influenza Vaccine in Healthy Volunteers

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

EARLY_PHASE1

Total Enrollment

36 participants

Study Classification

INTERVENTIONAL

Study Start Date

2024-03-01

Study Completion Date

2024-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study, a pilot randomized controlled trial, single-blind (outcome assessor), evaluating the immune response (both humoral and cell-mediated) against SARS-CoV-2 and the safety of three different vaccine administration approaches: the SARS-CoV-2 mRNA vaccine alone, the influenza vaccine alone, and the co-administration of both vaccines.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Immunogenicity and Safety Study of Self-amplifying mRNA COVID-19 Vaccine Administered With Influenza Vaccines in Adults

NCT06279871

COVID-19

COMPLETED PHASE3

A Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Combined Modified RNA Vaccine Candidate Against COVID-19 and Influenza.

NCT06178991

Influenza COVID-19

COMPLETED PHASE3

Immunogenicity and Safety of Concomitant Administration of Bivalent COVID-19 Vaccines With Influenza Vaccines

NCT05970887

Immune Response Safety

COMPLETED PHASE4

A Study to Learn About a Combined COVID-19 and Influenza Shot in Healthy Adults

NCT06237049

Influenza, Human SARS-CoV-2 Infection COVID-19

COMPLETED PHASE2

A Study of mRNA-based Influenza and SARS-CoV-2 (COVID-19) Multi-component Vaccines in Healthy Adults

NCT05827926

SARS-CoV-2 Influenza

COMPLETED PHASE1/PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

COVID - 19

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

SINGLE

Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Bivalent mRNA BNT162b2

Administering a booster dose of the bivalent mRNA vaccine BNT162b2.

Group Type ACTIVE_COMPARATOR

Bivalent mRNA SARS-CoV-2 vaccine

Intervention Type BIOLOGICAL

Administering a booster dose of the bivalent mRNA vaccine BNT162b2

Quardrivalent influenza vaccine

Administering a VaxigripTetra™

Group Type EXPERIMENTAL

Quardrivalent influenza vaccine

Intervention Type BIOLOGICAL

Administering a VaxigripTetra™

Co-administration

Co-administering bivalent mRNA vaccine BNT162b2 and VaxigripTetra™

Group Type EXPERIMENTAL

Bivalent mRNA SARS-CoV-2 vaccine

Intervention Type BIOLOGICAL

Administering a booster dose of the bivalent mRNA vaccine BNT162b2

Quardrivalent influenza vaccine

Intervention Type BIOLOGICAL

Administering a VaxigripTetra™

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Bivalent mRNA SARS-CoV-2 vaccine

Administering a booster dose of the bivalent mRNA vaccine BNT162b2

Intervention Type BIOLOGICAL

Quardrivalent influenza vaccine

Administering a VaxigripTetra™

Intervention Type BIOLOGICAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Thai adults aged 18-60 years, who have vaccinated COVID-19 and influenza vaccine more than 6 months.
* The subjects are able to and willing to comply with the requirements of the clinical trial program and could complete the 1-month follow-up of the study.
* Individuals who are in good health condition at the time of entry into the trial as determined by medical history, physical examination and clinical judgment of the investigator and meet the requirements of immunization.
* The subject can provide with informed consent and sign informed consent form (ICF).

Exclusion Criteria

* Have history of influenza or COVID-19 infection within 6 months.
* Have the medical history or family history of convulsion, epilepsy, encephalopathy, and psychosis.
* Be allergic to any component of the research vaccines or used to have a history of hypersensitivity or serious reactions to vaccination.
* History of Guillain-Barré syndrome.
* Women with positive urine pregnancy test, pregnant or breast-feeding, or have a pregnancy plan within six months of after baseline period.
* Have infectious diseases, including HIV and SARS-CoV-2 infection or any symptom of common cold.
* Have history of SARS-CoV-2 infection less than 6 months.
* Having severe chronic diseases or condition in progress cannot be controlled. For example, poor controlled DM and uncontrolled HT.
* Have the history of urticaria 1 year before receiving the investigational vaccine.
* Have known underlying diseases of thrombocytopenia or other coagulation disorders (which may cause contraindications for intramuscular injection).
* Having needle sickness.
* Have the history of immunosuppressive therapy, cytotoxic therapy, or systemic corticosteroids.
* Have received blood products within 4 months before injection of investigational vaccines.
* Under anti-tuberculosis treatment.
* Not be able to follow the protocol, or not be able to understand the informed consent according to the researcher's judgment, due to various medical, psychological, social, or other conditions.

Minimum Eligible Age

18 Years

Maximum Eligible Age

60 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes